Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

tors presented positive results from Phase 2 clinical trials of Amigal at the American College of Medical Genetics (ACMG) meeting. The data showed that Amigal was generally safe and well-tolerated at all doses evaluated and no drug-related serious adverse events were reported. In addition, Amigal increased the level of the enzyme deficient in Fabry patients in 24 of 26 study subjects, and in a majority of study subjects the treatment resulted in a reduction of kidney GL-3 as measured in urine.

Amicus, along with its partner Shire, has initiated discussions with the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) regarding its plans for Phase 3 clinical evaluation of Amigal. Amicus expects to complete these interactions and provide an update in the second half of 2008, and subject to the outcome of the discussions, the Company plans to initiate the Phase 3 clinical trial in the first half of 2009.

In parallel with the regulatory process, 23 of the original 26 patients continue to be treated with Amigal in the voluntary Phase 2 extension study to monitor long term safety and efficacy. In addition, the Company will evaluate modified doses and dose regimens in these 23 patients. Data from this extension study are expected to be available by Q1 2009, prior to finalization of the Phase 3 protocol.

Gaucher Disease:

Plicera(TM) (isofagomine tartrate) is an investigational, oral therapeutic being developed for the treatment of Gaucher disease. At the ACMG meeting in March, clinical investigators presented full data from a 4 week Phase 2 study in Gaucher patients who switched from enzyme replacement therapy (ERT) with imiglucerase to the pharmacological chaperone Plicera. Results showed that Plicera was generally safe and well tolerated at all doses and increased target enzyme activity levels in a majority of patients. In the trial, GCase activity, as measured in white blood cells, was increased in 20 of the 26 pat
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Rogne Bioscience, a privately-held biotechnology company based ... has acquired a licence to anti-inflammatory peptides from Isis ... anti-inflammatory activity of the peptides was discovered by Professor ... Sir William Dunn School of Pathology. ... million in seed financing, is developing a first-in-class, topical ...
(Date:7/31/2014)... CollabRx, Inc. (NASDAQ: CLRX), a leading ... oncology, today announced that it will hold an investor ... Company's financial results for the first quarter of fiscal ... in the current fiscal year. , The dial-in number ... 14, 2014, at 5 p.m. EDT (2 p.m. PDT) ...
(Date:7/31/2014)... San Diego, CA (PRWEB) July 31, 2014 ... company announced today the integration of Omicsoft’s Array Suite ... to both platforms will be able to send data ... The integration works with all versions of tranSMART including ... of the art statistics, visualization and storage for the ...
(Date:7/31/2014)... 31, 2014 SoundConnect , ... company, is proud to announce the addition of ... Adobe Connect’s elearning tools to quickly deploy and ... with training tools for desktop and mobile learning ... is the perfect online training solution, enabling organizations ...
Breaking Biology Technology:Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2
... 7, 2011 Cellectis (Alternext: ALCLS), the ... its nuclease production capacity has increased ten-fold ... of the nuclease manufacturing gives Cellectis bioresearch, ... of Cellectis, the potential to supply the ...
... , Inc. ( www.sermo.com ), the largest online physician ... of Sermo Sponsorship, a portfolio of offerings that provides ... to engage physicians and educate them on new products ... and mobile platforms, where physicians across 68 specialties discuss ...
... Sanford Rose Associates® - San Diego, focusing exclusively on assignments ... another successful placement. Mr. John Sperzel has been selected for ... a global provider of Point of Care testing systems and ... Directors. Mr. Sperzel is a dynamic business leader ...
Cached Biology Technology:Cellectis Announces a Ten-Fold Increase in Nuclease Production Capacity in 2011 2Sermo, Inc. Introduces New Sponsorship Product for Pharma, Biotech and Life Sciences 2Sermo, Inc. Introduces New Sponsorship Product for Pharma, Biotech and Life Sciences 3John Sperzel Appointed as Chief Executive Officer of ITC Nexus Dx 2
(Date:7/31/2014)... are the largest minority group in the United States, ... Latinos are obese and are 1.2 times as likely ... NYU College of Nursing student researcher Lauren Gerchow, BSN, ... that contribute to this problem by compiling a systematic ... in Latina women recently published in Nursing Research ...
(Date:7/31/2014)... study (HPV-023; NCT00518336) shows the sustained efficacy, ... virus (HPV) vaccine Cervarix. Women vaccinated with ... more than nine years, and vaccine efficacy ... is the longest follow-up report for a ... for the full paper. , HPV ...
(Date:7/31/2014)... team of scientists from Spain, France, and the ... that is the oldest definitive member of the ... amber. The discovery and description were made possible ... synchrotron imaging technique, which allows the detailed study ... new species is described in the journal ...
Breaking Biology News(10 mins):NYU research looks to combat US Latina immigrant obesity 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... in spite of waves that sometimes pound the shore ... 600 miles per hour are more prone to snap ... the American Association for the Advancement of Science meeting in ... reported that the fibrous threads she calls "nature,s bungee cords" ...
... or impacted wisdom teeth? As we humans evolved ... brains and shorter jaws, bear big babies and live longer, ... becoming the world,s most successful primate, at nearly 7 billion ... help us better deal with issues from obesity to difficult ...
... the University of Huddersfield aims to ensure that the risk of ... lead plumbing is reduced even further in line with new ... The project is being conducted in collaboration with Yorkshire ... such as European nations and the USA, have similar issues with ...
Cached Biology News:Mussels cramped by environmental factors 2Mussels cramped by environmental factors 3Is there a Neanderthal in the house? 2Research with Yorkshire Water to reduce lead in water supplies 2
Applications: (+) Immunocytochemistry and immunohistochemistry...
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
Non-Protein Peroxidase Stabilizer , 1 L...
... Lysate contains the cellular components necessary for ... elongation and termination factors) but has not ... is used primarily for the isolation of ... of endogenous globin mRNA. Untreated Lysate is ...
Biology Products: